Log In
BCIQ
Print this Print this
 

Triumec, Triumeq, dolutegravir/abacavir/lamivudine (572-Trii) (S-349572/S-265744/S-247303)

  Manage Alerts
Collapse Summary General Information
Company ViiV Healthcare Ltd.
DescriptionOnce-daily tablet that comprises Tivicay dolutegravir, an HIV integrase inhibitor, plus the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir and lamivudine
Molecular Target HIV integrase
Mechanism of ActionHIV integrase inhibitor; HIV reverse transcriptase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationHIV / AIDS
Indication DetailsTreat HIV-1 infection; Treat HIV/AIDS
Regulatory Designation U.S. - Undisclosed Review (Treat HIV-1 infection);
EU - Standard Review (Treat HIV-1 infection);
Japan - Standard Review (Treat HIV/AIDS)
PartnerShionogi & Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
Get a free BioCentury trial today